Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Animal-health turnaround with Q1 2026 revenue up 15% YoY and guidance raised for revenue, adjusted EBITDA, adjusted EPS, innovation revenue, and net leverage; recent product launches/approvals and unusual options activity support near-term attention into 2026-08-05 earnings.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Strong Cash Flow ⢠Elevated Leverage ELAN's improving profitability, margins, and cash flow support a cautiously constructive outlook, but high leverage, thin interest coverage, and intangible-heavy assets warrant risk-aware positioning.
Price Behavior
Key Price Behavior Insights: ⢠Above moving average ⢠$25.10 resistance ⢠$23.90 support Support Level: $23.90â$24.00; secondary $23.55â$23.65 Resistance Level: $25.08â$25.10 ELAN remains mildly bullish over the last month above $23.78, but a breakout above $25.10 is needed to confirm upside while a drop below $23.90 could weaken momentum.
Sentiment & News
Key News Insights: ⢠Raised Outlook ⢠Product Momentum ⢠Capacity Expansion Elanco's strong product momentum, raised outlook, capacity expansion, and deleveraging efforts support a constructive long-term outlook despite recent share-price volatility.
AI Summary
ELAN's investment case has shifted to proving that companion-animal launches and Ascend-driven 21% EBITDA margins can sustain free-cash-flow-led deleveraging, making confirmation of recurring GAAP earnings and leverage below 3x more important than headline revenue growth before underwriting a re-rating.
Description
Elanco Animal Health Inc. develops, manufactures and markets pharmaceuticals, vaccines and nutritional health products for companion animals and food-producing species, including treatments for parasites, infectious disease and common chronic conditions. The company distributes through third-party distributors, veterinarians and farm producers across beef, dairy, pork, poultry and aquaculture markets; it was founded in 1954 and is headquartered in Greenfield, Indiana.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 21 | Jul 28 | ELAN | Elanco Animal Health Incorporated | Animal-health turnaround with Q1 2026 revenue up 15% YoY and guidance raised for revenue, adjusted EBITDA, adjusted EPS, innovation revenue, and net leverage; recent product launches/approvals and unusual options activity support near-term attention into 2026-08-05 earnings. | Closed | +0.2% |
| Jun 24 | Jul 1 | ELAN | Elanco Animal Health Incorporated | Multiple fresh animal-health catalysts: on 2026-05-06 Elanco raised full-year 2026 revenue, adjusted EBITDA, and adjusted EPS guidance; on 2026-06-15 USDA approved TruCan Ultra Lyme-L4 with shipping expected within 30 days; Q1 2026 margins and profitability improved, supporting a constructive short-term setup. | Closed | +0.5% |
| Jun 12 | Jun 19 | ELAN | Elanco Animal Health Incorporated | Animal-health guidance raise with product catalysts: Q1 2026 revenue grew 15% YoY to $1.371B, management raised 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and innovation revenue, while new launches such as Advantage Collar for Dogs and Befrena support near-term sentiment. Stock is up about 12% over 21 trading days. | Closed | +0.2% |
| Jun 5 | Jun 12 | ELAN | Elanco Animal Health Incorporated | Animal-health recovery with concrete catalysts: Q1 2026 revenue grew 15% YoY to $1.371B and management raised full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and year-end leverage. New products including Befrena and Advantage Collar plus the New World screwworm backdrop add timely sector support. | Closed | +2.3% |